Psychemedics Corporation Share Price

Equities

PMD

US7443752057

Healthcare Facilities & Services

Market Closed - Nasdaq 12:25:23 18/06/2024 am IST 5-day change 1st Jan Change
2.273 USD +1.01% Intraday chart for Psychemedics Corporation +0.12% -23.22%
Sales 2022 25.24M 2.11B Sales 2023 22.1M 1.85B Capitalization 17.17M 1.43B
Net income 2022 -1M -83.53M Net income 2023 -4M -334M EV / Sales 2022 1.05 x
Net cash position 2022 1.18M 98.23M Net Debt 2023 334K 27.9M EV / Sales 2023 0.79 x
P/E ratio 2022
-25.5 x
P/E ratio 2023
-4.09 x
Employees 116
Yield 2022
5.71%
Yield 2023
2.36%
Free-Float 69.32%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.01%
1 week+0.12%
Current month-5.30%
1 month-11.91%
3 months-23.47%
6 months-20.53%
Current year-23.22%
More quotes
1 week
2.23
Extreme 2.2304
2.33
1 month
2.23
Extreme 2.23
2.69
Current year
2.23
Extreme 2.23
3.93
1 year
2.06
Extreme 2.06
5.15
3 years
2.06
Extreme 2.06
8.90
5 years
2.06
Extreme 2.06
10.73
10 years
2.06
Extreme 2.06
27.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 17/23/17
Director of Finance/CFO 34 27/11
Corporate Officer/Principal 38 21/23/21
Members of the board TitleAgeSince
Director/Board Member 62 12/22/12
Chairman 66 12/22/12
Director/Board Member 63 16/21/16
More insiders
Date Price Change Volume
18/24/18 2.273 +1.01% 1 484
14/24/14 2.25 -2.60% 753
13/24/13 2.31 0.00% 978
12/24/12 2.31 +2.21% 3,947
11/24/11 2.26 -0.44% 3,633

Delayed Quote Nasdaq, June 18, 2024 at 12:25 am IST

More quotes
Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.
More about the company